What is diffuse large B-cell lymphoma (DLBCL)?

Diffuse large B-cell lymphoma, or DLBCL, is a type of aggressive lymphoma that affects B cells. B cells are white blood cells that protect your body from infection.

In DLBCL, B cells can grow and multiply uncontrollably

Healthy vs cancerous B-cells in diffuse large B-cell lymphoma (DLBCL)

For illustrative purposes. Populations of cancerous cells differ from patient to patient.

Although DLBCL can occur at any age, its occurrence increases with age. Most people are first diagnosed between the ages of 65 and 74.

DLBCL can affect both men and women, although it is slightly more common in men.

The cause of DLBCL is unknown.

What does relapsed or refractory (R/R) mean?

Relapse happens when the cancer or the signs and symptoms of the cancer return after responding to previous treatment.

Refractory refers to a disease that has not responded to previous treatment.

Relapsed or refractory diffuse large B-cell lymphoma is often referred to as R/R DLBCL.

Additional resources

Treatment Guide: Learn more about POLIVY and relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Treatment guide download for POLIVY® (polatuzumab vedotin-piiq)

You can learn more about cancer by visiting the websites below:

American Cancer Society 1-800-ACS-2345 (1-800-227-2345)
www.cancer.org
CancerCare 1-800-813-HOPE (1-800-813-4673)
www.cancercare.org
National Comprehensive Cancer Network www.nccn.org/patients

 


Genentech is neither affiliated with nor endorses any of these third-party organizations. We do not make any representation or guarantee as to the accuracy of the information on sites not controlled by Genentech. These links are provided for informational purposes only.


POLIVY® (polatuzumab vedotin-piiq) effectiveness icon - see the efficacy results of POLIVY+BR

Results in R/R DLBCL

See the efficacy results of POLIVY+BR

POLIVY® (polatuzumab vedotin-piiq) icon for how it may work

How Does POLIVY Work?

Learn about how POLIVY was designed to treat R/R DLBCL

POLIVY® (polatuzumab vedotin-piiq) icon for financial support

Financial Support

Learn about financial assistance and other resources to help you access POLIVY

Indication

POLIVY is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat diffuse large B-cell lymphoma in adults who have progressed after at least 2 prior therapies.

The conditional approval of POLIVY is based on a type of response rate. There are ongoing studies to establish how well the drug works.

Possible serious side effects

Everyone reacts differently to POLIVY therapy, so it’s important to know what the side effects are. Some people who have been treated with POLIVY have experienced serious to fatal side effects. Your doctor may stop or adjust your treatment if any serious side effects occur. Be sure to contact your healthcare team if there are any signs of these side effects.

  • Nerve problems in your arms and legs: This may happen as early as after your first dose and may worsen with every dose. Your doctor will monitor for signs and symptoms, such as changes in your sense of touch, numbness or tingling in your hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to your walking pattern
  • Infusion-related reactions: You may experience fever, chills, rash, breathing problems, low blood pressure, or hives within 24 hours of your infusion
  • Infections: If you have a fever of 100.4°F (38°C) or higher, chills, cough, or pain during urination, contact your healthcare team. Your doctor may also give you medication before giving you POLIVY, which may prevent some infections, and will monitor your blood counts throughout treatment with POLIVY. Treatment with POLIVY can cause severe low blood cell counts
  • Rare and serious brain infections: Your doctor will monitor closely for signs and symptoms of these types of infections. Contact your doctor if you experience confusion, dizziness or loss of balance, trouble talking or walking, or vision changes
  • Tumor lysis syndrome: Caused by the fast breakdown of cancer cells. Signs include nausea, vomiting, diarrhea, and lack of energy
  • Potential harm to liver: Some signs include tiredness, weight loss, pain in the abdomen, dark urine, and yellowing of your skin or the white part of your eyes. You may be at higher risk if you already had liver problems or you are taking other medication

Side effects seen most often

The most common side effects during treatment were

  • Low blood cell counts (platelets, red blood cells, white blood cells)
  • Nerve problems in arms and legs
  • Tiredness or lack of energy
  • Diarrhea
  • Nausea
  • Fever
  • Decreased appetite
  • Infections

POLIVY may not be for everyone. Talk to your doctor if you are

  • Pregnant or think you are pregnant: Data have shown that POLIVY may harm your unborn baby
  • Planning to become pregnant: Women should avoid getting pregnant while taking POLIVY. Women should use effective contraception during treatment and for at least 3 months after their last POLIVY treatment. Men taking POLIVY should use effective contraception during treatment and for at least 5 months after their last POLIVY treatment
  • Breastfeeding: Women should not breastfeed while taking POLIVY and for at least 2 months after the last dose

These may not be all the side effects. Talk to your healthcare provider for more information about the benefits and risks of POLIVY treatment.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see the full Prescribing Information for additional Important Safety Information.